InMode Ltd. (INMD) Stock Score, Valuation & Financial Research
InMode Ltd. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 44/100.
Quick answer for INMD
InMode Ltd. currently has a Wall Street Score of 44/100. The stored market price is $14.9. Its financial score is 39/100. Its valuation score is 26/100. The latest WSS change is -0.3 points. These figures are a research snapshot, not a buy or sell recommendation.
What InMode Ltd. does
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite i
INMD financial snapshot
- Wall Street Score:
- 44/100
- Current price:
- $14.9
- Market capitalization:
- $856.5M
- Revenue:
- $374.6M
- Net income:
- $77.5M
- Free cash flow:
- $84.3M
- Cash:
- $396.2M
- Total debt:
- $4.5M
- EPS:
- 1.45
- P/E ratio:
- 10.3x
- Financial score:
- 39/100
- Valuation score:
- 26/100
- Revenue score:
- 23/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $84.3M, showing positive cash generation.
- The balance sheet shows $396.2M of cash versus $4.5M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.3 points: INMD decreased 0.3 points because Revenue declined by 2.2 points.
What the numbers mean
Its current valuation score is 26/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research INMD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.